Regenxbio completes dosing in phase 1 trial of gene therapy for wet AMD

Dosing is complete in a phase 1 clinical trial of RGX-314, a gene therapy treatment for wet age-related macular degeneration, according to a press release from Regenxbio.
The fourth cohort of six patients brings the total number of subjects in the dose-escalation trial to 24, the release said. The multicenter, open-label, multiple-cohort clinical trial is assessing the safety and tolerability of RGX-314 as a one-time therapy for patients with previously treated wet AMD and is being completed at seven retinal surgery centers across the United States.
“We continue to be (Read more...)

Full Story →